Skip to main content
. 2018 Apr 26;103(2):222–226. doi: 10.1136/bjophthalmol-2018-311887

Table 4.

Changes between baseline and month 24 in ETDRS level, by study endpoint

Phenotype Endpoint # Patients DR worsening DR improving No change
All ≥3 steps Two steps One step All One step Two steps ≥3 steps
A (n=87) No CIMO 86 (98.9%) 17 (19.8) 0 4 13 30 (34.9) 13 1 16 39 (45.3)
CIMO 1 (1.1%) 0 (0.0) 0 0 0 0 (0.0) 0 0 0 1 (100.0)
B (n=45) No CIMO 32 (71.1%) 2 (6.3) 0 0 2 8 (25.0) 6 0 2 22 (68.8)
CIMO 13 (28.9%) 2 (15.4) 1 0 1 3 (23.1) 1 0 2 8 (61.5)
C (n=17) No CIMO 12 (70.6) 4 (33.3) 0 3 1 2 (16.7) 1 0 1 6 (50.0)
CIMO 5 (29.4%) 3 (60.0) 2 1 0 0 (0.0) 0 0 0 2 (40.0)

CIMO, central-involved macular oedema; DR, diabetic retinopathy; ETDRS, Early Treatment Diabetic Retinopathy Study.